Loading clinical trials...
Loading clinical trials...
52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Noden Pharma
NCT07365332 · Pulmonary Arterial Hypertension
NCT02417740 · Cystic Fibrosis, Immunologic Deficiency Syndrome, and more
NCT07218029 · Pulmonary Arterial Hypertension
NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension
NCT06647511 · Gestational Hypertension
Novartis Investigative Site
Birmingham, Alabama
Novartis Investigative Site
Little Rock, Arkansas
Novartis Investigative Site
Dalton, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions